LOGIN  |  REGISTER
Astria Therapeutics
Compass Therapeutics

Sonida Senior Living to Participate in Citi’s 30th Annual Global Property CEO Conference

February 17, 2025 | Last Trade: US$25.00 0.50 2.04

DALLAS / Feb 17, 2025 / Business Wire / Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in senior living communities, announced today that Brandon Ribar, President & Chief Executive Officer, Kevin Detz, Chief Financial Officer and Max Levy, Chief Investment Officer, will participate in Citi’s 30th Annual Global Property CEO Conference on Monday, March 3rd through Wednesday, March 5th at the Diplomat Resort & Spa Hollywood in Florida.

Management will be available for one-on-one meetings with institutional investors during the conference. To schedule a meeting, please contact your bank representative.

In addition, Mr. Ribar is scheduled to participate in a moderated roundtable discussion on Wednesday, March 5th from 8:10 a.m. – 8:45 a.m. EST.

About Sonida

Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 94 senior housing communities in 20 states with an aggregate capacity of over 10,000 residents, including 81 communities which the Company owns (including eight communities in which the Company owns varying interests through two separate joint ventures), and 13 communities that the Company manages on behalf of a third-party.

For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, X or LinkedIn. 

Assertio

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page